CVAC NASDAQ
CureVac N.V.
1W: +7.4%
1M: -13.1%
3M: -16.3%
1Y: +42.6%
3Y: -28.1%
5Y: -95.5%
$4.66
Last traded 2025-12-31 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$535M
+895.5% ▲
5Y CAGR: +98.4%
Gross Profit
$429M
+708.1% ▲
Operating Income
$178M
+164.8% ▲
Net Income
$162M
+162.3% ▲
EPS (Diluted)
$0.72
+161.0% ▲
EBITDA
$210M
+189.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $49M | $103M | $67M | $54M | $535M |
| YoY Growth | +180.8% | +110.6% | -34.5% | -20.3% | +895.5% |
| Cost of Revenue | $14M | $238M | $184M | $124M | $106M |
| Gross Profit | $35M | -$135M | -$117M | -$71M | $429M |
| Gross Margin | 71.0% | -131.3% | -172.9% | -131.3% | 80.2% |
| R&D Expenses | $114M | $816M | $63M | $116M | $153M |
| SG&A Expenses | $46M | $89M | $89M | $76M | $74M |
| Operating Expenses | $159M | $277M | $134M | $204M | $252M |
| Operating Income | -$124M | -$412M | -$249M | -$274M | $178M |
| Operating Margin | -253.6% | -400.3% | -370.0% | -510.1% | 33.2% |
| Interest Expense | $22M | $10M | $4M | $2M | $0 |
| Income Before Tax | -$130M | -$412M | -$249M | -$260M | $191M |
| Tax Expense | -$726K | -$782K | -$126K | $198K | $29M |
| Net Income | -$129M | -$412M | -$249M | -$260M | $162M |
| Net Margin | -264.0% | -399.8% | -369.4% | -484.0% | 30.3% |
| EPS (Diluted) | $-0.98 | $-2.21 | $-1.32 | $-1.18 | $0.72 |
| EBITDA | -$123M | -$386M | -$209M | -$234M | $210M |
| Shares Outstanding | 132M | 186M | 189M | 221M | 225M |